OMEROS

pharmaceuticals, namely-- surgical and burn management compositions containing pharmacologic agents for the inhibition of pain, inflammation, cartilage loss, smooth muscle spasm and/or tumor cell adhesion associated with surgical procedures and other trauma; chondroprotective compositions containing pharmacologic agents for the treatment or inhibition of cartilage loss, pain and/or inflammation; intravascular compositions containing pharmacologic agents for the inhibition of vasospasm and/or restenosis; and drug delivery systems, namely combinations of pharmacologic agents or genes and their carriers for the treatment and inhibition of pain, inflammation, cartilage loss, smooth muscle spasm, tumor cell adhesion, vasospasm and/or restenosis